Peak Bio, Inc. announced that it has entered into a securities purchase agreement to issue convertible note on December 18, 2023. The company may close the transaction in one or two tranches. The company shall, at each closing of the offering of the Convertible Notes, pay a cash commission equal to 8% of the gross proceeds received by the Company from Qualified Investors from such closing.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0086 USD | 0.00% | 0.00% | -95.41% |
03-05 | Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc.. | CI |
02-16 | Peak Bio, Inc. announced that it has received $2.238 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-95.41% | 199K | |
+52.36% | 58.06B | |
-3.86% | 40.53B | |
+36.67% | 38.99B | |
-12.01% | 26.56B | |
+14.13% | 26.7B | |
-21.62% | 18.98B | |
+0.21% | 12.17B | |
+25.96% | 11.92B | |
+23.02% | 12B |
- Stock Market
- Equities
- PKBO Stock
- News Peak Bio, Inc.
- Peak Bio, Inc. announced a financing transaction